News
VERA
--
0.00%
--
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data In Two Oral Presentations At The 59th European Renal Association Congress
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association Congress Atacicept is the first known investigational therapy to decrease both
Benzinga · 1d ago
Vera Therapeutics GAAP EPS of -$0.71 misses by $0.07
Vera Therapeutics press release (NASDAQ:VERA): Q1 GAAP EPS of -$0.71 misses by $0.07. Vera reported approximately $151 million in cash, cash equivalents and marketable securities as of March 31, 2022
Seekingalpha · 5d ago
Vera Therapeutics: Q1 Earnings Insights
  Vera Therapeutics (NASDAQ:VERA) reported its Q1 earnings results on Monday, May 16, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 5d ago
BRIEF-Vera Therapeutics Reports Qtrly Loss Per Share $0.71
reuters.com · 5d ago
Vera Therapeutics to Present at Upcoming Conferences in May 2022
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announ...
GlobeNewswire · 05/05 20:05
Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022
BRISBANE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announc...
GlobeNewswire · 05/02 23:06
--HC Wainwright Starts Vera Therapeutics at Buy With $35 Price Target
MT Newswires · 05/02 06:36
--Wedbush Starts Vera Therapeutics at Outperform With $32 Price Target
MT Newswires · 04/19 04:56
Vera Therapeutics GAAP EPS of -$0.79
Vera Therapeutics press release (NASDAQ:VERA): Q4 GAAP EPS of -$0.79. Cash and cash equivalents of $79.7M as of December 31, 2021
Seekingalpha · 03/24 11:01
Vera Therapeutics Q4 Net Loss Narrows
MT Newswires · 03/24 06:43
Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D., World-Renowned Transplant Nephrologist and Pioneering Kidney Transplant Researcher
Management to provide overview of MAU868, its lead asset in the treatment of BK Virus infections in kidney transplant patients BK Virus is a leading cause of transplant loss and transplant-associated morbidity KOL webinar to be held Tuesday, March 29, 2022...
GlobeNewswire · 03/21 11:30
Vera Therapeutics to Host Business Update Call
BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, will host ...
GlobeNewswire · 03/17 11:30
Ralph Lauren, PVH and Under Armour lead drops across apparel and footwear stocks
The selling pressure in the stock market hit the apparel sector on Friday, particularly with some higher-end names. Concerns on lower demand in Europe and inflation headwinds hit Capri Holdings
Seekingalpha · 03/04 16:37
Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference
BRISBANE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today ...
GlobeNewswire · 03/01 12:30
We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 02/22 10:29
Insiders Buy Around $112M Of 3 Stocks
US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades.
Benzinga · 02/15 11:55
Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced t...
GlobeNewswire · 02/14 21:01
Vera Therapeutics drops 14% on upsized public offering of ~4.99M
Vera Therapeutics (NASDAQ:VERA) prices its public offering of 4,993,067 shares at a price of $15.00 per share. Underwriters 30-day option to purchase up to an additional 748,959 shares. Gross proceeds are
Seekingalpha · 02/10 13:59
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
BRISBANE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”) (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, to...
GlobeNewswire · 02/10 13:46
Vera Therapeutics Prices $74.9 Million Stock Offering; Shares Drop
MT Newswires · 02/10 10:43
Webull provides a variety of real-time VERA stock news. You can receive the latest news about Vera Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About VERA
Vera Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease, and early death. It is also developing MAU868, a monoclonal antibody that neutralizes infection with BK Virus.